KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Accumulated Expenses (2020 - 2025)

Royalty Pharma (RPRX) has disclosed Accumulated Expenses for 6 consecutive years, with $110.8 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 13.01% to $110.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $110.8 million through Dec 2025, up 13.01% year-over-year, with the annual reading at $110.8 million for FY2025, 13.01% up from the prior year.
  • Accumulated Expenses hit $110.8 million in Q4 2025 for Royalty Pharma, up from $29.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $110.8 million in Q4 2025 to a low of $10.3 million in Q1 2021.
  • Historically, Accumulated Expenses has averaged $42.2 million across 5 years, with a median of $40.7 million in 2021.
  • Biggest five-year swings in Accumulated Expenses: surged 204.98% in 2024 and later fell 24.39% in 2025.
  • Year by year, Accumulated Expenses stood at $57.7 million in 2021, then fell by 6.13% to $54.2 million in 2022, then dropped by 4.58% to $51.7 million in 2023, then surged by 89.74% to $98.1 million in 2024, then increased by 13.01% to $110.8 million in 2025.
  • Business Quant data shows Accumulated Expenses for RPRX at $110.8 million in Q4 2025, $29.0 million in Q3 2025, and $85.6 million in Q2 2025.